Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil

Author:

Shafaee Maryam Nemati1ORCID,Silva Leonardo Roberto2,Ramalho Susana2,Doria Maira Teixeira3,De Andrade Natal Rodrigo2,Cabello Victor2,Cons Livia2,Pavanello Marina4,Zeferino Luiz Carlos2,Mano Max S5,Linck Rudinei Diogo Marques5,Batista Leticia Souza5,Pedro Estela Pantarotto5,De Paula Bruno Henrique6,Zuca-Matthes Gustavo7,Podany Emily1,Makawita Shalini8,Ann Stewart Kelsey9,Tsavachidis Spiridon1,Tamimi Rull10,Bondy Melissa11,Debord Logan12,Ellis Matthew1,Bines Jose6,Cabello Cesar2

Affiliation:

1. Baylor College of Medicine, Houston, TX, USA

2. Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil

3. Department of Obstetrics and Gynecology, Clinical Hospital of Federal University of Paraná, Curitiba, Paraná, Brazil

4. School of Women’s and Children’s Health, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia

5. Hospital Sírio-Libanês, São Paulo, Brazil

6. Instituto Nacional Do Câncer (INCA – HCIII), Rio de Janeiro, Brazil

7. Barretos Cancer Hospital, Barretos, Brazil

8. MD Anderson Cancer Center, Houston, TX, USA

9. Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA

10. Department of Population Health Sciences, Weill Cornell Medicine, New York-Presbyterian, New York, NY, USA

11. Center for Population Health Sciences, Stanford Cancer Institute, Stanford, CA, USA

12. Department of Dermatology, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA

Abstract

Abstract Background Breast cancer outcomes among patients who use safety-net hospitals in the highly populated Harris County, Texas and Southeast Brazil are poor. It is unknown whether treatment delay contributes to these outcomes. Methods We conducted a retrospective cohort analysis of patients with non-metastatic breast cancer diagnosed between January 1, 2009 and December 31, 2011 at Harris Health Texas and Unicamp’s Women’s Hospital, Barretos Hospital, and Brazilian National Institute of Cancer, Brazil. We used Cox proportional hazards regression to evaluate association of time to treatment and risk of recurrence (ROR) or death. Results One thousand one hundred ninety-one patients were included. Women in Brazil were more frequently diagnosed with stage III disease (32.3% vs. 21.1% Texas; P = .002). Majority of patients in both populations had symptom-detected disease (63% in Brazil vs. 59% in Texas). Recurrence within 5 years from diagnosis was similar 21% versus 23%. Median time from diagnosis to first treatment defined as either systemic therapy (chemotherapy or endocrine therapy) or surgery, were comparable, 9.9 weeks versus 9.4 weeks. Treatment delay was not associated with increased ROR or death. Higher stage at diagnosis was associated with both increased ROR and death. Conclusion Time from symptoms to treatment was considerably long in both populations. Treatment delay did not affect outcomes. Impact Access to timely screening and diagnosis of breast cancer are priorities in these populations.

Funder

Lester and Sue Smith Breast Center

T32 Institutional Training Grant

Susan G. Komen Travel Scholarship

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Brasil Finance Code

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference62 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Epidemiological characteristics of and risk factors for breast cancer in the world;Momenimovahed;Breast Cancer,2019

3. The global breast cancer burden: variations in epidemiology and survival;Hortobagyi;Clin Breast Cancer,2005

4. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019

5. Trends in breast cancer mortality by stage at diagnosis among young women in the United States;Guo;Cancer,2018

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3